Regulatory submission is based on positive results from the Phase 2 PROSPECT Study —– FDA sets PDUFA Date of December 18, 2026 —OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera ...
Explore the differences between emerging HER2-targeted TKIs, Zongertinib and Seviberatinib, and their therapeutic implications in cancer treatment. Stay ahead of policy, cost, and value—subscribe to ...
GLP-1 RA use is associated with reduced risk for CRC compared with aspirin, with consistent benefit seen in subgroups in sensitivity analyses. HealthDay News — Glucagon-like peptide-1 receptor agonist ...
ICP-332, an investigational tyrosine kinase 2 inhibitor, demonstrated favorable safety and resulted in more than a 70% reduction in Eczema Area and Severity Index (EASI) scores in a randomized phase 2 ...
The only GLP-1 RA agent to show significant benefit for colorectal cancer incidence risk was semaglutide. HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a ...
Hetero Labs Ltd. has identified angiopoietin-1 receptor (TEK; hTIE2), EGFR (HER1; erbB1), hepatocyte growth factor receptor (HGFR; MET), proto-oncogene tyrosine-protein kinase receptor ret (RET; ...
ADELAIDE, South Australia, AUSTRALIA, 6 January 2026 -- A genetic mutation passed from mother to children in families affected by schizophrenia has now been shown to completely silence a brain ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results